Efficacy and tolerability of gemtuzumab ozogamicin (anti-CD33 monoclonal antibody, CMA-676, Mylotarg(®)) in children with relapsed/refractory myeloid leukemia

BACKGROUND: Gemtuzumab ozogamicin (GO) is a cytotoxic anti-CD33 monoclonal antibody that has given promising preliminary results in adult myeloid CD33+ AML. We conducted a retrospective multicenter study of 12 children treated with GO on a compassionate basis (median age 5.5 y). Three patients (2 MD...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Brethon, Benoit, Auvrignon, Anne, Galambrun, Claire, Yakouben, Karima, Leblanc, Thierry, Bertrand, Yves, Leverger, Guy, Baruchel, André
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2006
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC1523361/
https://ncbi.nlm.nih.gov/pubmed/16805911
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-6-172
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars